



THERAPEUTIC EXPERIENCE

- Allergies
- Alzheimer's disease
- Anxiety disorders
- Bipolar disorder
- Cardiovascular disease
- Depression
- Diabetes
- Hypertension
- Mild cognitive impairment
- Ophthalmology
- Pain models and management
- Parkinson's disease
- Women's health studies

OVERVIEW

Founded by physicians committed to advancing medical science, Worldwide is out to change how the world sees CROs — in the best possible way. From Bioanalytical Sciences through Phase IIa trials, our Early Phase Services include a 300-bed clinical site in San Antonio, Texas that is GCP/ICH compliant. Specimens are seamlessly transferred internally, or to a lab of your choice, for sample bioanalysis. We never compromise on science or safety. We're never satisfied with the status quo. We're the Cure for the Common CRO.

FACILITY CAPABILITIES

- Centralized atomic clock system
- Class 10,000 clean room
- Federal and State Schedule I-V Drug Licensure
- Fully equipped sample processing laboratory
- Full-service clinical laboratory
- Limited access Phase I unit
- Serial and continuous CSF equipment
- Security alarmed -70°C and -20°C freezers
- Spacious procedure areas
- Telemetry equipment

PHASE I-IIA

Our Early Phase Services' staff has enrolled thousands of participants for both inpatient and outpatient trials. Our staff works closely with you to customize data entry and other processes to meet your specific needs. Our 85,000-square-foot center in San Antonio, Texas, contains extensive security measures to ensure that study drug supplies, patient information, study samples and associated documentation remain confidential and secure. Our ability to accommodate large study populations or multiple cohort trials, combined with our dedicated, experienced staff, enables effective integrated planning and implementation for Phase I-IIa clinical trials.

BIOEQUIVALENCE STUDIES

Early Phase Services' comprehensive services for bioequivalence studies include protocol design and development, clinical conduct, bioanalysis and statistical analysis. Our final study reports for FDA submission are produced using Liquent InSight Publisher™, which automatically compiles source documents with varying file formats into one seamless publication. This technology also supports reporting from Thermo Electron Watson™ LIMS and other software programs.



PHASE I-IIA STUDY CAPABILITIES

- Pharmacokinetics/pharmacodynamics
- First-in-man
- Bioavailability
- Bioequivalence
- Dose ranging
- Multiple dose tolerance
- Drug-drug interactions
- ADME studies

PHARMACOKINETIC AND STATISTICAL SERVICES

- Pharmacokinetic and pharmacokinetic/pharmacodynamic modeling
- Noncompartmental analysis
- Bioequivalence and bioavailability testing
- Preclinical (toxicokinetics) and clinical pharmacokinetics
- Determining the effects of dosing regimen, patient demographics, etc. on pharmacokinetics
- Interim safety and pharmacokinetic analysis for early phase/*first-in-man* studies
- Experience in ADME studies, plasma and urine pharmacokinetics, dose escalation (SAD), multiple dose (MAD), toxicokinetic (preclinical), *first-in-man*, bioavailability and bioequivalence

BIOSTATISTICAL SERVICES

- Design and implementation of randomization scheme
- Development of Statistical Analysis Plan (SAP)
- Sample size rationale and statistical power
- Methodology for summary and analysis of demographic, baseline, efficacy and safety data
- Description of statistical methodology
- SAS programming for tables, listings and figures
- Production of tables, listings and graphs in compliance with ICH guidelines
- Performance and validation of statistical analysis
- Interim analysis
- Bioequivalence
- Linear and non-linear modeling
- Parametric and non-parametric analysis of clinical and PK endpoints
- Production of statistical report/assistance with clinical report
- Statistical management throughout the project

